Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CUMBERLAND PHARMACEUTICALS INCCPIX · Entity 6757 | Director | March 18, 2026 | March 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CUMBERLAND PHARMACEUTICALS INC
Report date March 18, 2026 · Filed March 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 46,863 |
Reported balance
After 2026-03-18 transaction · row 1
1 source rowRow 1 · 2026-03-18 · Grant · Acquired 1,800 · Balance 46,863 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 08, 2022 Filed Aug 19, 2022 21:31 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 43 | $2.21 | $95.03 |
DisclosureSEC source: 0001209191-22-046898 · doc4.xml · nonDerivative · entry 5 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,400 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| July 07, 2022 Filed Aug 19, 2022 21:31 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 43 | $2.18 | $93.74 |
DisclosureSEC source: 0001209191-22-046898 · doc4.xml · nonDerivative · entry 4 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,357 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| July 06, 2022 Filed Aug 19, 2022 21:31 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 43 | $2.11 | $90.73 |
DisclosureSEC source: 0001209191-22-046898 · doc4.xml · nonDerivative · entry 3 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,314 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| July 05, 2022 Filed Aug 19, 2022 21:31 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 43 | $2.18 | $93.74 |
DisclosureSEC source: 0001209191-22-046898 · doc4.xml · nonDerivative · entry 2 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,271 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| July 01, 2022 Filed Aug 19, 2022 21:31 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 30 | $2.11 | $63.30 |
DisclosureSEC source: 0001209191-22-046898 · doc4.xml · nonDerivative · entry 1 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,228 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| June 30, 2022 Filed Jul 1, 2022 19:09 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 42 | $2.08 | $87.36 |
DisclosureSEC source: 0001209191-22-040104 · doc4.xml · nonDerivative · entry 21 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,198 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| June 29, 2022 Filed Jul 1, 2022 19:09 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 42 | $2.11 | $88.62 |
DisclosureSEC source: 0001209191-22-040104 · doc4.xml · nonDerivative · entry 20 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,156 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| June 28, 2022 Filed Jul 1, 2022 19:09 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 37 | $2.06 | $76.22 |
DisclosureSEC source: 0001209191-22-040104 · doc4.xml · nonDerivative · entry 19 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,114 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| June 27, 2022 Filed Jul 1, 2022 19:09 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 7 | $2.06 | $14.42 |
DisclosureSEC source: 0001209191-22-040104 · doc4.xml · nonDerivative · entry 18 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,077 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| June 24, 2022 Filed Jul 1, 2022 19:09 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 42 | $2.11 | $88.62 |
DisclosureSEC source: 0001209191-22-040104 · doc4.xml · nonDerivative · entry 17 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,070 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| June 23, 2022 Filed Jul 1, 2022 19:09 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 42 | $2.01 | $84.42 |
DisclosureSEC source: 0001209191-22-040104 · doc4.xml · nonDerivative · entry 16 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,028 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| June 22, 2022 Filed Jul 1, 2022 19:09 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 39 | $1.99 | $77.61 |
DisclosureSEC source: 0001209191-22-040104 · doc4.xml · nonDerivative · entry 15 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,986 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| June 21, 2022 Filed Jul 1, 2022 19:09 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 42 | $1.97 | $82.74 |
DisclosureSEC source: 0001209191-22-040104 · doc4.xml · nonDerivative · entry 14 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,947 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| June 17, 2022 Filed Jul 1, 2022 19:09 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 40 | $1.94 | $77.60 |
DisclosureSEC source: 0001209191-22-040104 · doc4.xml · nonDerivative · entry 13 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,905 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| June 16, 2022 Filed Jul 1, 2022 19:09 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 40 | $1.95 | $78.00 |
DisclosureSEC source: 0001209191-22-040104 · doc4.xml · nonDerivative · entry 12 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,865 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| June 15, 2022 Filed Jul 1, 2022 19:09 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 40 | $1.98 | $79.20 |
DisclosureSEC source: 0001209191-22-040104 · doc4.xml · nonDerivative · entry 11 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,825 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| June 14, 2022 Filed Jul 1, 2022 19:09 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 40 | $2.02 | $80.80 |
DisclosureSEC source: 0001209191-22-040104 · doc4.xml · nonDerivative · entry 10 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,785 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| June 13, 2022 Filed Jul 1, 2022 19:09 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 40 | $2.01 | $80.40 |
DisclosureSEC source: 0001209191-22-040104 · doc4.xml · nonDerivative · entry 9 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,745 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| June 10, 2022 Filed Jul 1, 2022 19:09 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 40 | $2.04 | $81.60 |
DisclosureSEC source: 0001209191-22-040104 · doc4.xml · nonDerivative · entry 8 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,705 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| June 09, 2022 Filed Jul 1, 2022 19:09 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 40 | $2.09 | $83.60 |
DisclosureSEC source: 0001209191-22-040104 · doc4.xml · nonDerivative · entry 7 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,665 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| June 08, 2022 Filed Jul 1, 2022 19:09 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 40 | $2.12 | $84.80 |
DisclosureSEC source: 0001209191-22-040104 · doc4.xml · nonDerivative · entry 6 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,625 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| June 07, 2022 Filed Jul 1, 2022 19:09 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 30 | $2.08 | $62.40 |
DisclosureSEC source: 0001209191-22-040104 · doc4.xml · nonDerivative · entry 5 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,585 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| June 06, 2022 Filed Jul 1, 2022 19:09 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 40 | $2.07 | $82.80 |
DisclosureSEC source: 0001209191-22-040104 · doc4.xml · nonDerivative · entry 4 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,555 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| June 03, 2022 Filed Jul 1, 2022 19:09 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 38 | $2.09 | $79.42 |
DisclosureSEC source: 0001209191-22-040104 · doc4.xml · nonDerivative · entry 3 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,515 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| June 02, 2022 Filed Jul 1, 2022 19:09 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 38 | $2.08 | $79.04 |
DisclosureSEC source: 0001209191-22-040104 · doc4.xml · nonDerivative · entry 2 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,477 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| June 01, 2022 Filed Jul 1, 2022 19:09 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 38 | $2.05 | $77.90 |
DisclosureSEC source: 0001209191-22-040104 · doc4.xml · nonDerivative · entry 1 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,439 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| May 31, 2022 Filed Jun 10, 2022 21:05 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 38 | $2.13 | $80.94 |
DisclosureSEC source: 0001209191-22-036001 · doc4.xml · nonDerivative · entry 21 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,401 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| May 27, 2022 Filed Jun 10, 2022 21:05 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 38 | $2.13 | $80.94 |
DisclosureSEC source: 0001209191-22-036001 · doc4.xml · nonDerivative · entry 20 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,363 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| May 26, 2022 Filed Jun 10, 2022 21:05 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 38 | $2.12 | $80.56 |
DisclosureSEC source: 0001209191-22-036001 · doc4.xml · nonDerivative · entry 19 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,325 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| May 25, 2022 Filed Jun 10, 2022 21:05 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 38 | $2.15 | $81.70 |
DisclosureSEC source: 0001209191-22-036001 · doc4.xml · nonDerivative · entry 18 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,287 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| May 24, 2022 Filed Jun 10, 2022 21:05 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 38 | $2.17 | $82.46 |
DisclosureSEC source: 0001209191-22-036001 · doc4.xml · nonDerivative · entry 17 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,249 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| May 23, 2022 Filed Jun 10, 2022 21:05 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 38 | $2.17 | $82.46 |
DisclosureSEC source: 0001209191-22-036001 · doc4.xml · nonDerivative · entry 16 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,211 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| May 20, 2022 Filed Jun 10, 2022 21:05 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 34 | $2.23 | $75.82 |
DisclosureSEC source: 0001209191-22-036001 · doc4.xml · nonDerivative · entry 15 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,173 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| May 19, 2022 Filed Jun 10, 2022 21:05 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 34 | $2.29 | $77.86 |
DisclosureSEC source: 0001209191-22-036001 · doc4.xml · nonDerivative · entry 14 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,139 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| May 18, 2022 Filed Jun 10, 2022 21:05 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 34 | $2.31 | $78.54 |
DisclosureSEC source: 0001209191-22-036001 · doc4.xml · nonDerivative · entry 13 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,105 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| May 17, 2022 Filed Jun 10, 2022 21:05 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 34 | $2.35 | $79.90 |
DisclosureSEC source: 0001209191-22-036001 · doc4.xml · nonDerivative · entry 12 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,071 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| May 16, 2022 Filed Jun 10, 2022 21:05 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 34 | $2.31 | $78.54 |
DisclosureSEC source: 0001209191-22-036001 · doc4.xml · nonDerivative · entry 11 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,037 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| May 13, 2022 Filed Jun 10, 2022 21:05 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 34 | $2.32 | $78.88 |
DisclosureSEC source: 0001209191-22-036001 · doc4.xml · nonDerivative · entry 10 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,003 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| May 12, 2022 Filed Jun 10, 2022 21:05 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 34 | $2.23 | $75.82 |
DisclosureSEC source: 0001209191-22-036001 · doc4.xml · nonDerivative · entry 9 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,969 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| May 11, 2022 Filed Jun 10, 2022 21:05 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 34 | $2.37 | $80.58 |
DisclosureSEC source: 0001209191-22-036001 · doc4.xml · nonDerivative · entry 8 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,935 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| May 10, 2022 Filed Jun 10, 2022 21:05 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 34 | $2.55 | $86.70 |
DisclosureSEC source: 0001209191-22-036001 · doc4.xml · nonDerivative · entry 7 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,901 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| May 09, 2022 Filed Jun 10, 2022 21:05 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 34 | $2.63 | $89.42 |
DisclosureSEC source: 0001209191-22-036001 · doc4.xml · nonDerivative · entry 6 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,867 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| May 06, 2022 Filed Jun 10, 2022 21:05 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 30 | $2.36 | $70.80 |
DisclosureSEC source: 0001209191-22-036001 · doc4.xml · nonDerivative · entry 5 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,833 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| May 05, 2022 Filed Jun 10, 2022 21:05 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 30 | $2.35 | $70.50 |
DisclosureSEC source: 0001209191-22-036001 · doc4.xml · nonDerivative · entry 4 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,803 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| May 04, 2022 Filed Jun 10, 2022 21:05 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 30 | $2.37 | $71.10 |
DisclosureSEC source: 0001209191-22-036001 · doc4.xml · nonDerivative · entry 3 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,773 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| May 03, 2022 Filed Jun 10, 2022 21:05 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 30 | $2.42 | $72.60 |
DisclosureSEC source: 0001209191-22-036001 · doc4.xml · nonDerivative · entry 2 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,743 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| May 02, 2022 Filed Jun 10, 2022 21:05 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 30 | $2.45 | $73.50 |
DisclosureSEC source: 0001209191-22-036001 · doc4.xml · nonDerivative · entry 1 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,713 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| April 29, 2022 Filed May 6, 2022 21:08 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 30 | $2.44 | $73.20 |
DisclosureSEC source: 0001209191-22-027649 · doc4.xml · nonDerivative · entry 11 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,683 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| April 28, 2022 Filed May 6, 2022 21:08 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 30 | $2.51 | $75.30 |
DisclosureSEC source: 0001209191-22-027649 · doc4.xml · nonDerivative · entry 10 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,653 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| April 27, 2022 Filed May 6, 2022 21:08 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 30 | $2.41 | $72.30 |
DisclosureSEC source: 0001209191-22-027649 · doc4.xml · nonDerivative · entry 9 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,623 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.